litlas
Log inCreate account

Eric Leip

Active 2001–2025

47
Papers
20,373
Citations
38
h-index
46
i10-index

Citations

Citations per year for Eric Leip1979: 1 citations1995: 1 citations1999: 1 citations2000: 6 citations2001: 10 citations2002: 29 citations2003: 84 citations2004: 124 citations2005: 142 citations2006: 186 citations2007: 208 citations2008: 186 citations2009: 174 citations2010: 164 citations2011: 178 citations2012: 172 citations2013: 188 citations2014: 155 citations2015: 153 citations2016: 149 citations2017: 146 citations2018: 114 citations2019: 409 citations2020: 368 citations2021: 397 citations2022: 295 citations2023: 255 citations2024: 488 citations2025: 229 citations2026: 9 citations1980–1994: no citations, so these years are not shown1996–1998: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,224 citing papers, 27.6% of this breakdownUnited Kingdom: 582 citing papers, 7.2% of this breakdownGermany: 435 citing papers, 5.4% of this breakdownItaly: 407 citing papers, 5.1% of this breakdownChina: 369 citing papers, 4.6% of this breakdownCanada: 350 citing papers, 4.3% of this breakdownNetherlands: 310 citing papers, 3.9% of this breakdownAustralia: 289 citing papers, 3.6% of this breakdownFrance: 271 citing papers, 3.4% of this breakdownJapan: 225 citing papers, 2.8% of this breakdownSpain: 202 citing papers, 2.5% of this breakdownSweden: 179 citing papers, 2.2% of this breakdown
0%27.6%Other 27.4%

Institutions

Fields

  • Medicine87%
  • Biochemistry, Genetics and Molecular Biology5.4%
  • Engineering1.1%
  • Health Professions1.1%
  • Immunology and Microbiology1%
  • Nursing1%
  • Other3.4%

Topics

  • Atrial Fibrillation Management and Outcomes6.4%
  • Cardiovascular Function and Risk Factors5.3%
  • Heart Failure Treatment and Management5.3%
  • Blood Pressure and Hypertension Studies5.1%
  • Cardiac Arrhythmias and Treatments2.6%
  • Chronic Myeloid Leukemia Treatments2.4%
  • Other72.9%

Coauthors

All papers

Open in search
  1. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

    Authors: Alexander M. Lesokhin, Michael H. Tomasson, Bertrand Arnulf, Nizar J. Bahlis, H. Miles Prince, Rubén Niesvizky, Paula Rodríguez‐Otero, Joaquín Martínez‐López, Guenther Koehne, Cyrille Touzeau, Yogesh Jethava, Hang Quach, Julien Depaus, Hisayuki Yokoyama, Afshin Eli Gabayan, Don A. Stevens, Ajay K. Nooka, Salomon Manier, Noopur Raje, Shinsuke Iida, Marc S. Raab, Emma Searle, Eric Leip, Sharon T. Sullivan, Umberto Conte, Mohamed Elmeliegy, Akos Czibere, Andrea Viqueira, Mohamad Mohty - Nature Medicine 2023 cited by 564

  2. Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality

    Authors: Thomas J. Wang, Martin G. Larson, Daniel Levy, Ramachandran S. Vasan, Eric Leip, Philip A. Wolf, Ralph B. D’Agostino, Joanne M. Murabito, William B. Kannel, Emelia J. Benjamin - Circulation 2003 cited by 1,966

  3. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial

    Authors: Jörge E. Cortes, Carlo Gambacorti‐Passerini, Michael W. Deininger, Michael J. Mauro, Charles Chuah, Dong‐Wook Kim, Iryna Dyagil, Nataliia Glushko, Dragana Milojković, Philipp le Coutre, Valentín García‐Gutiérrez, Laurence Reilly, Allison Jeynes-Ellis, Eric Leip, Nathalie Bardy‐Bouxin, Andreas Hochhaus, Tim H. Brümmendorf - Journal of Clinical Oncology 2017 cited by 493

  4. Lifetime Risk for Developing Congestive Heart Failure

    Authors: Donald M. Lloyd‐Jones, Martin G. Larson, Eric Leip, Alexa Beiser, Ralph B. D’Agostino, William B. Kannel, Joanne M. Murabito, Ramachandran S. Vasan, Emelia J. Benjamin, Daniel Levy - Circulation 2002 cited by 1,610

  5. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial

    Authors: Tim H. Brümmendorf, Jörge E. Cortes, Dragana Milojković, Carlo Gambacorti‐Passerini, Richard E. Clark, Philipp le Coutre, Valentín García‐Gutiérrez, Charles Chuah, Vamsi Kota, Jeffrey H. Lipton, Philippe Rousselot, Michael J. Mauro, Andreas Hochhaus, Rafael Hurtado Monroy, Eric Leip, Simon Purcell, Anne Yver, Andrea Viqueira, Michael W. Deininger, BFORE study investigators - Leukemia 2022 cited by 141

  6. Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age

    Authors: Donald M. Lloyd‐Jones, Eric Leip, Martin G. Larson, Ralph B. D’Agostino, Alexa Beiser, Peter W.F. Wilson, Philip A. Wolf, Daniel Levy - Circulation 2006 cited by 1,310

  7. Lifetime Risk for Development of Atrial Fibrillation

    Authors: Donald M. Lloyd‐Jones, Thomas J. Wang, Eric Leip, Martin G. Larson, Daniel Levy, Ramachandran S. Vasan, Ralph B. D’Agostino, Joseph M. Massaro, Alexa Beiser, Philip A. Wolf, Emelia J. Benjamin - Circulation 2004 cited by 2,042

  8. Impact of Obesity on Plasma Natriuretic Peptide Levels

    Authors: Thomas J. Wang, Martin G. Larson, Daniel Levy, Emelia J. Benjamin, Eric Leip, Peter W.F. Wilson, Ramachandran S. Vasan - Circulation 2004 cited by 1,027

  9. Plasma Natriuretic Peptide Levels and the Risk of Cardiovascular Events and Death

    Authors: Thomas J. Wang, Martin G. Larson, Daniel Levy, Emelia J. Benjamin, Eric Leip, Torbjørn Omland, Philip A. Wolf, Ramachandran S. Vasan - New England Journal of Medicine 2004 cited by 1,537

  10. Impact of High-Normal Blood Pressure on the Risk of Cardiovascular Disease

    Authors: Ramachandran S. Vasan, Martin G. Larson, Eric Leip, Jane C. Evans, Christopher J. O’Donnell, W B Kannel, Daniel Levy - New England Journal of Medicine 2001 cited by 2,094

  11. Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies.

    Authors: Ajay K. Nooka, Alexander M. Lesokhin, Mohamad Mohty, Rubén Niesvizky, Christopher Maisel, Bertrand Arnulf, Sarah Larson, Asya Varshavsky Yanovsky, Xavier Leleu, Lionel Karlin, David H. Vesole, Nizar J. Bahlis, Carlos Fernández de Larrea, Noopur Raje, Eric Leip, Umberto Conte, Mohamed Elmeliegy, Andrea Viqueira, Salomon Manier - Journal of Clinical Oncology 2023 cited by 42

  12. Framingham risk score and prediction of lifetime risk for coronary heart disease

    Authors: Donald M. Lloyd‐Jones, Peter W.F. Wilson, Martin G. Larson, Alexa Beiser, Eric Leip, Ralph B. D’Agostino, Daniel Levy - The American Journal of Cardiology 2004 cited by 581

  13. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study

    Authors: Andreas Hochhaus, Carlo Gambacorti‐Passerini, Camille N. Abboud, Bjørn Tore Gjertsen, Tim H. Brümmendorf, B. Douglas Smith, Thomas Ernst, Pilar Giraldo-Castellano, Ulla Olsson‐Strömberg, Susanne Saußele, Nathalie Bardy‐Bouxin, Andrea Viqueira, Eric Leip, T. Alexander Russell-Smith, Jocelyn M Leone, Gianantonio Rosti, Justin M. Watts, Francis J. Giles, on behalf of the BYOND Study Investigators, Elisabetta Abruzzese, L Akard, Alberto Bosi, F. Cervantes, Aude Charbonnier, Francesco Di Raimondo, Gabriel Etienne, V. Garcia Gutierrez, Agnès-Paule Guerci-Bresler, Henrik Hjorth‐Hansen, Jean Michel Karsenti, Kevin R. Kelly, P. Le Coutre, Carmen Martínez Chamorro, Vivian G. Oehler, G. Orti Pascual, Andreas Petzer, Ester Pungolino, Giovanna Rege‐Cambrin, Françoise Rigal‐Huguet, Gail J. Roboz, P. Rousselot, Fermín Sánchez‐Guijo, Guillermo Sanz Santillana, Philippe Schafhausen, C. Scheid, Stefan Schmidt, Giorgina Specchia, Juan Luis Steegmann, Leif Stenke - Leukemia 2020 cited by 83

  14. Long-Term Efficacy and Safety of Elranatamab Monotherapy in the Phase 2 Magnetismm-3 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)

    Authors: Michael H. Tomasson, Shinsuke Iida, Rubén Niesvizky, Mohamad Mohty, Nizar J. Bahlis, Joaquín Martínez‐López, Guenther Koehne, Paula Rodríguez‐Otero, H. Miles Prince, Andrea Viqueira, Eric Leip, Umberto Conte, Sharon T. Sullivan, Alexander M. Lesokhin - Blood 2023 cited by 28

  15. Does the Relation of Blood Pressure to Coronary Heart Disease Risk Change With Aging?

    Authors: Stanley S. Franklin, Martin G. Larson, Shehzad Akbar Khan, Nathan D. Wong, Eric Leip, William B. Kannel, Daniel Levy - Circulation 2001 cited by 1,389

  16. Impact of age and sex on plasma natriuretic peptide levels in healthy adults

    Authors: Thomas J. Wang, Martin G. Larson, Daniel Levy, Eric Leip, Emelia J. Benjamin, Peter W.F. Wilson, Patrice Sutherland, Torbjørn Omland, Ramachandran S. Vasan - The American Journal of Cardiology 2002 cited by 472

  17. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

    Authors: Jörge E. Cortes, Hagop M. Kantarjian, Tim H. Brümmendorf, Dong‐Wook Kim, Anna Turkina, Zhi-Xiang Shen, Ricardo Pasqüini, H. Jean Khoury, Steven Arkin, Angela Volkert, Nadine Besson, Richat Abbas, Junyuan Wang, Eric Leip, Carlo Gambacorti‐Passerini - Blood 2011 cited by 461

  18. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

    Authors: H. Jean Khoury, Jörge E. Cortes, Hagop M. Kantarjian, Carlo Gambacorti‐Passerini, Michele Baccarani, Dong‐Wook Kim, Andrey Zaritskey, Athena Countouriotis, Nadine Besson, Eric Leip, Virginia Kelly, Tim H. Brümmendorf - Blood 2012 cited by 318

  19. Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study

    Authors: Michael H. Tomasson, Shinsuke Iida, Rubén Niesvizky, Mohamad Mohty, Nizar J. Bahlis, Joaquín Martínez‐López, Guenther Koehne, Paula Rodríguez‐Otero, H. Miles Prince, Andrea Viqueira, Eric Leip, Umberto Conte, Sharon T. Sullivan, Alexander M. Lesokhin - HemaSphere 2024 cited by 61

  20. Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort

    Authors: Sebastian Grosicki, Ulf‐Henrik Mellqvist, Łukasz Pruchniewski, Jacob Crafoord, Suzanne Trudel, Chang‐Ki Min, Darrell White, Adrían Alegre, Markus Hansson, Takashi Ikeda, Kazutaka Sunami, Eric Leip, Arthur J. Kudla, Gregory Finn, Youngil Koh - Blood 2022 cited by 31

  21. Plasma Natriuretic Peptides for Community Screening for Left Ventricular Hypertrophy and Systolic Dysfunction

    Authors: Ramachandran S. Vasan, Emelia J. Benjamin, Martin G. Larson, Eric Leip, Thomas J. Wang, Peter W.F. Wilson, Daniel Levy - JAMA 2002 cited by 497

  22. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study

    Authors: Ramachandran S. Vasan, Martin G. Larson, Eric Leip, William B. Kannel, Daniel Levy - The Lancet 2001 cited by 1,068

  23. Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study

    Authors: Nizar J. Bahlis, Michael H. Tomasson, Mohamad Mohty, Rubén Niesvizky, Ajay K. Nooka, Salomon Manier, Christopher Maisel, Yogesh Jethava, Joaquín Martínez‐López, H. Miles Prince, Bertrand Arnulf, Paula Rodríguez‐Otero, Guenther Koehne, Cyrille Touzeau, Noopur Raje, Shinsuke Iida, Marc‐Steffen Raab, Eric Leip, Sharon T. Sullivan, Umberto Conte, Andrea Viqueira, Alexander M. Lesokhin - Blood 2022 cited by 52

  24. Long‐term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome‐positive leukemias treated with bosutinib

    Authors: Jörge E. Cortes, H. Jean Khoury, Hagop M. Kantarjian, Tim H. Brümmendorf, Michael J. Mauro, Ewa Matczak, Dmitri Pavlov, Jean M. Aguiar, Kolette D. Fly, Svetoslav Dimitrov, Eric Leip, Mark Shapiro, Jeff H. Lipton, Jean‐Bernard Durand, Carlo Gambacorti‐Passerini - American Journal of Hematology 2016 cited by 95